Stocks Sanofi SA

More

  • Early movers: AA, MEG, WMB, BHI, VOD, NVO & more Monday, 28 Sep 2015 | 7:48 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • PARIS, Sept 28- French drugmaker Sanofi said the European Commission had cleared its key cholesterol drug Praluent for the treatment of so-called "bad cholesterol," or low-density lipoprotein cholesterol, in certain adult patients with hypercholesterolemia.

  • Sept 25- The U.S. Food and Drug Administration on Friday approved Danish drugmaker Novo Nordisk's diabetes drug Tresiba, two years after rejecting the long-acting form of insulin. Novo Nordisk is the world's No. 1 maker of insulin, a hormone normally produced by the pancreas that helps the body use glucose for energy. U.S.-listed shares of Novo Nordisk fell 10...

  • BOSTON, Sept 24- Top U.S. heart doctors said on Thursday that newly developed cholesterol treatments that cost more than $14,000 per year are best used for the small group of patients for which they have been approved, at least for now. CVS Health, a pharmacy benefit manager, has set out a program that aims to limit the drug's use and has said that it would try to use...

  • Sept 24- GlaxoSmithKline Plc said the European health regulator had recommended an approval for its injectable drug to treat asthma patients who don't respond well to traditional inhalers. GSK and other drugmakers including AstraZeneca Plc, Roche Holding AG, Teva Pharmaceutical Industries Ltd and Sanofi SA are developing drugs that take a more...

  • Details of the case are being presented on Thursday at the annual meeting of the European Association for the Study of Diabetes in Stockholm by Michael Yafi, director of paediatric endocrinology at the University of Texas, Houston. Diabetes is a growing problem worldwide with the number of diabetics estimated to be 387 million in 2014 and forecast to soar to...

  • The Boston- based group clinched a royalty-based financing deal in April valuing the company at $5.5 billion, more than any other unlisted emerging biotechnology business in history. Full results from two of these, showing ITCA 650 to be more effective than Merck's Januvia in controlling blood sugar levels, were presented at the European Association for the...

  • LONDON, Sept 16- Swiss drugmaker Roche has big ambitions beyond treating cancer, where it is already global market leader, and believes it has a winner in a new multiple sclerosis drug. So far, Roche has only said that ocrelizumab hit its targets in final-stage clinical trials by cutting relapses and disability progression when compared with Merck KGaA's...

  • NIMH director to leave for Google Life Sciences Tuesday, 15 Sep 2015 | 2:29 PM ET

    Sept 15- National Institutes of Mental Health director Dr Tom Insel said he will step down in November and join Google Inc's life sciences division. Google has been increasing its presence in the healthcare industry, signing deals with drugmakers including Novartis AG and Sanofi SA. The life sciences division is collaborating with Novartis to develop...

  • Sept 11- Amgen Inc said on Friday it had asked the U.S. Food and Drug Administration to approve a monthly single-dosing option for its recently approved cholesterol drug, Repatha. At the time of approval, Amgen had said it planned to make the monthly dosing option available next year. Amgen's drug is being launched in Europe at around half the U.S. price.

  • Sept 11- Amgen Inc said it had asked the U.S. Food and Drug Administration to approve a monthly single-dosing option for its recently approved cholesterol drug, Repatha. At the time of approval, Amgen had said it planned to make the monthly dosing option available next year. Repatha competes with a similar drug from Regeneron Pharmaceuticals Inc and Sanofi SA,...

  • *Merck pulled plug on cladribine in 2011 towards end of Phase III. *Oral MS drugs from Biogen, Novartis with more than $2 bln sales. FRANKFURT, Sept 11- Germany's Merck KGaA is to seek approval from Europe's regulators for the use of its cladribine tablet to treat multiple sclerosis, in a fresh attemp to enter a multi-billion dollar market for a drug it had given up on...

  • The Boston- based Institute for Clinical and Economic Review said its analyses indicated "that the price that best represents the overall benefits" the drugs may provide patients would be between $3,615 and $4,811 a year, a 67 percent discount off the list prices. Praluent from Regeneron Pharmaceuticals and Sanofi has a U.S. price of $14,600 for a year of...

  • The Boston- based Institute for Clinical and Economic Review said its analyses indicated "that the price that best represents the overall benefits" the drugs may provide patients would be between $3,615 and $4,811 a year, a 67 percent discount off the list prices. Praluent from Regeneron Pharmaceuticals and Sanofi has a U.S. price of $14,600 for a year of...

  • Sept 3- Genzyme Corp agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant Seprafilm, the Department of Justice said on Thursday. Sanofi bought Genzyme in 2011.. According to papers filed with the federal court in Tampa, Florida, Genzyme admitted and...

  • Sept 3- Genzyme Corp agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant Seprafilm, the Department of Justice said on Thursday. Sanofi bought Genzyme in 2011.. According to papers filed with the federal court in Tampa, Florida, Genzyme admitted and...

  • Insulin infusion device maker CeQur raises $100 mln Tuesday, 1 Sep 2015 | 6:53 AM ET

    LONDON, Sept 1- Privately held company CeQur, which is developing the world's first three-day insulin infusion device for people with type 2 diabetes, has raised $100 million in a funding round that shows strong investor appetite for hot medical technology. The patch-like insulin infusion device offers an alternative to daily insulin injections made by the...

  • Google, Sanofi team up to improve diabetes care Monday, 31 Aug 2015 | 10:26 AM ET

    Aug 31- Google Inc and French drugmaker Sanofi SA said they will partner to develop tools to improve the management and treatment of diabetes. Sanofi will work with Google's life sciences team to collect, analyze and understand information impacting diabetes, which is expected to affect 592 million by 2035, according to the International Diabetes...

  • Results with Alnylam Pharmaceuticals and Medicines Co's experimental product ALN-PCSsc highlight the competition for a market tipped to generate billions of dollars in sales. Amgen's Repatha and a rival product, Praluent, from Sanofi and Regeneron Pharmaceuticals, are each expected to generate more than $2 billion a year in sales by 2020, according to...

  • WASHINGTON, Aug 27- The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those at high risk of cardiovascular disease. Last month the FDA approved a similar drug from Regeneron Pharmaceuticals Inc and Sanofi SA. The drugs are expected to generate more than $2 billion a...